Prelude Therapeutics Inc (PRLD) is next scheduled to report earnings on Aug 13, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-0.23.
Heading into this report, the model's fair value estimate sits 14.0% above the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for PRLD from 2 independent valuation methods with sufficient data. 1 place fair value above the current price of $5.37, and 1 place it below. The model-blended estimate lands at $4.62 — a model fair value differential of 14.0% below the current price under these model assumptions. The methods are evenly split, reflecting genuine dispersion in the estimate.
Equity Rank's fundamental strength composite scores PRLD at 47.7/100 (C, Adequate), blending profitability, balance-sheet, and cash-flow quality.
Prelude Therapeutics Inc (PRLD) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator